MAPT and Alzheimer disease: These Aβ levels are all above thresholds generally considered to indicate abnormality (i.e., 14–20 CL), consistent with Aβ preceding tau accumulation in ADAD, as well as with findings from sporadic AD that Aβ appears to be a major driver of neocortical tau accumulation [16].